SLDB News and Press, Solid Biosciences Inc.

2024-07-15 14:48:06 ET More on Solid Biosciences Solid Biosciences rises 15% off expanded Sarepta Duchenne indication Seeking Alpha’s Quant Rating on Solid Biosciences Historical earnings data for Solid Biosciences Financial information for Solid Biosc...

2024-07-15 12:03:52 ET More on Lexeo Therapeutics Lexeo Therapeutics reports Q1 results IPO Roundup: Viking Holdings, RanMarine Technology, and more Historical earnings data for Lexeo Therapeutics Financial information for Lexeo Therapeutics Read th...

2024-07-06 13:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“...

CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as ...

2024-06-25 09:00:00 ET Summary Catalent stock rose 3% after Elevidys label expansion approval by the FDA. Sarepta's stock reached an all-time high after Elevidys label expansion approval. Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candid...

2024-06-21 09:12:53 ET More on Solid Biosciences Buy Solid Biosciences: Unpacking Its Main Value Driver Solid Biosciences gets FDA rare pediatric disease status for DMD therapy William Blair starts Solid Biosciences at outperform Seeking Alpha’s Quant ...

2024-06-21 08:15:07 ET Piper Sandler analyst issues OVERWEIGHT recommendation for SLDB on June 21, 2024 06:49AM ET. The previous analyst recommendation was Overweight. SLDB was trading at $6.3 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-05-31 06:00:08 ET Biren Amin from Piper Sandler issued a price target of $20.00 for SLDB on 2024-05-31 05:07:00. The adjusted price target was set to $20.00. At the time of the announcement, SLDB was trading at $7.64. The overall price target consensus is at $19.00 ...

2024-05-26 03:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...